VYGR - Voyager Therapeutics, Inc.
| Previous Close | 9.80 |
| Open | 9.90 |
| Bid | 9.53 x 2200 |
| Ask | 11.00 x 800 |
| Day's Range | 8.98 - 9.90 |
| 52 Week Range | 8.98 - 31.91 |
| Volume | 813,203 |
| Avg. Volume | 327,466 |
| Market Cap | 313.523M |
| Beta (3Y Monthly) | 3.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.48 |
| Earnings Date | May 7, 2018 - May 11, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.18 |
- GlobeNewswire•2 days ago
Voyager Therapeutics Joins Michael J. Fox Foundation Initiatives and Education Campaigns to Accelerate the Development of New therapies and a Cure for Parkinson’s Disease
Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced joining multiple partnerships with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) including the Parkinson’s Progression Markers Initiative (PPMI) and the Parkinson’s Disease Education Consortium (PDEC). “We are dedicated to finding a cure for Parkinson's disease and accelerating breakthroughs patients can feel in their everyday lives,” said Sohini Chowdhury, deputy chief executive officer of The Michael J. Fox Foundation.
- Insider Monkey•4 days ago
Should You Buy Voyager Therapeutics, Inc. (VYGR)?
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients’ money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth depends on it. Regardless of the various methods used by elite investors like David Tepper and Dan Loeb, […]
- GlobeNewswire•9 days ago
Voyager Therapeutics Announces First Patient Dosed in RESTORE-1, a Phase 2 Trial of VY-AADC Gene Therapy for the Treatment of Parkinson’s Disease
Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced dosing of the first patient in RESTORE-1, a Phase 2, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of VY-AADC for the treatment of Parkinson’s disease in patients with motor fluctuations that are refractory to medical management. “Patients with Parkinson’s disease need new therapeutic options, especially as the disease progresses and there is less AADC enzyme in parts of the brain where it is needed to convert levodopa to dopamine,” said Mark Richardson, M.D., Ph.D., Associate Professor, Director of Epilepsy and Movement Disorders Surgery at the University of Pittsburgh Medical Center and principal investigator in the RESTORE-1 trial.
- GlobeNewswire•20 days ago
Voyager Therapeutics Enters into Strategic Manufacturing Collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies
Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced that it has entered into collaborations with Brammer Bio (Brammer) and Fujifilm Diosynth Biotechnologies (Fujifilm) to further expand Voyager’s manufacturing capabilities to support the development of its gene therapy programs. The collaborations allow Voyager to transfer its state-of-the-art research and development production capabilities to best-in-class gene therapy contract development and manufacturing organizations (CDMO) with late-stage clinical and commercial-scale capabilities, particularly as it relates to the baculovirus/Sf9 system for manufacturing adeno-associated virus (AAV) gene therapies.
- GlobeNewswire•26 days ago
Report: Exploring Fundamental Drivers Behind Graphic Packaging Holding, QEP Resources, Inogen, CytRx, Voyager Therapeutics, and Daily Journal Corp. (S.C.) — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•29 days ago
Edited Transcript of VYGR earnings conference call or presentation 7-Nov-18 9:30pm GMT
Q3 2018 Voyager Therapeutics Inc Earnings Call
- GlobeNewswire•29 days ago
Voyager Therapeutics to Present at the Evercore ISI Healthcare Conference
CAMBRIDGE, Mass., Nov. 19, 2018 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.
- Benzinga•last month
The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 7) Allakos Inc (NASDAQ: ALLK ) BioTelemetry Inc (NASDAQ: ...
- Associated Press•last month
Voyager Therapeutics: 3Q Earnings Snapshot
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 63 cents. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
- GlobeNewswire•last month
Voyager Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Highlights
Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today reported its third quarter 2018 results, recent progress and corporate updates and will host a conference call and webcast today at 4:30 p.m. EST to discuss these results. “We made important progress advancing our innovative pipeline in the third quarter as we presented exciting new preclinical data with our Huntington’s disease and SOD1 ALS programs and today announced durable improvements in motor function at 18 months and beyond from the ongoing Phase 1b trial with VY-AADC in patients with Parkinson’s disease,” said Andre Turenne, president and chief executive officer of Voyager Therapeutics.
- GlobeNewswire•last month
Voyager Therapeutics Announces Positive Longer-Term Data for VY-AADC for Parkinson’s Disease
Patients in the two highest dose cohorts (Cohorts 3 and 2) experienced mean improvements in diary on-time without troublesome dyskinesia (good ON time) of 1.7 hours per day at 18 months and 2.7 hours per day at two years, respectively. Having selected a dose for the Phase 2 trial between the two highest dose cohorts from the Phase 1b trial, Voyager performed a combined analysis of the outcomes from the ten patients in Cohorts 2 and 3. This combined analysis demonstrated an increase from baseline in good ON time of 2.4 hours per day at 12 months, the timepoint for the primary endpoint in the Phase 2 trial, and 2.6 hours per day at 18 months, the latest timepoint measured for both cohorts.
- GlobeNewswire•2 months ago
Voyager Therapeutics to Host Third Quarter 2018 Financial Results and Corporate Highlights Conference Call
CAMBRIDGE, Mass., Oct. 31, 2018 -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.
- GlobeNewswire•2 months ago
Voyager Therapeutics Announces Preclinical Data for Huntington’s Disease and Amyotrophic Lateral Sclerosis Programs at the Congress of the European Society of Gene and Cell Therapy
For VY-HTT01, a novel delivery paradigm that targets both the putamen and thalamus significantly reduced huntingtin, or HTT, gene expression in both deeper tissues (caudate, putamen, and thalamus) and outer layers (cortex) of the brain of adult, non-human primates. Targeting both the putamen and thalamus leverages more extensive and preserved neuronal pathways to the cortex than delivery to the putamen alone, offering the potential of a one-time treatment with VY-HTT01 to address motor, cognitive and behavioral disabilities associated with Huntington’s disease.
- Simply Wall St.•3 months ago
Voyager Therapeutics Inc (NASDAQ:VYGR): Time For A Financial Health Check
The direct benefit for Voyager Therapeutics Inc (NASDAQ:VYGR), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-offRead More...
- Market Realist•3 months ago
Analysts Remain Bullish on BioMarin Pharmaceutical
Of the 23 analysts covering BioMarin Pharmaceutical (BMRN) in September, 19 of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for BioMarin stock is 1.78 with a target price of $119.35, implying an upside potential of 21.1% over its closing price of $98.58 on September 12.
Market Realist•3 months agoAnalyzing Audentes Therapeutics’ Valuation Metrics
Audentes Therapeutics (BOLD) incurred a net loss of $31.37 million in the second quarter compared with a net loss of $22.74 million in the second quarter of 2017. That translates to a net loss per share of $0.85 in the second quarter of 2018. Its net loss per share was $0.87 in the second quarter of 2017.
- Zacks•4 months ago
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -26.98% and -14.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•4 months ago
Voyager Therapeutics: 2Q Earnings Snapshot
The Cambridge, Massachusetts-based company said it had a loss of 80 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- ACCESSWIRE•4 months ago
Voyager Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Voyager Therapeutics, Inc. (NASDAQ: VYGR ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern ...
- ACCESSWIRE•5 months ago
Breakfast Technical Briefing on ZIOPHARM Oncology and Three Other Additional Biotech Stocks
For today, WallStEquities.com assesses vTv Therapeutics Inc. (NASDAQ: VTVT), Voyager Therapeutics Inc. (NASDAQ: VYGR), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Zosano Pharma Corp. (NASDAQ: ZSAN). High Point, North Carolina headquartered vTv Therapeutics Inc.'s stock saw a decline of 3.70%, finishing last Friday's trading session at $1.30. The Company's shares are trading below their 50-day moving average by 19.58%.
- Benzinga•5 months ago
Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus
The biotech space represents a gold mine of opportunity for investors to multiply their investment returns, courtesy of the volatility generated by market-moving catalysts. In a note this week, Canaccord ...
